News

Emyria’s data-backed cannabinoid treatments are changing lives

February 23, 2021

author:

Emyria’s data-backed cannabinoid treatments are changing lives

Emyria Limited (ASX: EMD) is an Australian drug development company that focuses on novel treatments for patients with unmet medical needs. The drug development programs are backed by proprietary clinical evidence, which is then used to inform future programs.

Emyria Limited (ASX: EMD) is an Australian drug development company that focuses on novel treatments for patients with unmet medical needs. The drug development programs are backed by proprietary clinical evidence, which is then used to inform future programs.

After many years in the clinical trial and drug development field, Emyria’s founding team saw an opportunity to do a better job of studying patients under novel treatments.

 

“We’ve pulled together a very unique combination of resources which positions us very strongly to do drug development in a really rapid, novel and accelerated way,” said CEO, Dr Michael Winlo on Reach Markets’ webcast series ‘The Insider’.

 

From a network of medical clinics across Australia, Emyria evaluates patients with unmet needs and provides them access to new, unregistered treatments in a clinical trial-grade setting.

“We invest heavily in the data platform within those clinics. That data informs smart and strategic drug development programs which we lead independently or at times with partners. That data also feeds back into our care models and allows us to provide a highly personalized and very unique care experience,” said Michael.

Through these clinics, Emyria has gathered well over 2.6 million data points.

 

“Our data is essentially the brains behind our operation. It allows us to do intelligent care delivery and very intelligent, highly strategic drug design,” he said.

 

Emyria’s primary focus is medicinal cannabis. The company has provided medicinal-grade cannabinoid products to over 3500 patients with 44 clinical indications.

Emyria is developing EMD-003, a low dose cannabinoid treatment that focuses on symptoms of psychological distress such as PTSD and major depression, both of which are major unmet needs. Having already captured unique intellectual property covering methods of use, the company is now planning for pivotal clinical registration trials.

“We feel that our data and also clinical trial expertise gives us a huge head start on this program,” said Michael.

 

“Our goal is to try to move the best products from medicinal cannabis into mainstream medicine, registered products that then can be available through a routine prescription,” he added.

 

Emyria’s CEO Dr Michael Winlo recently joined us for our fortnightly webcast ‘The Insider: Meet the CEOs’. This article summarises some of the information he shared with us during the session. You can watch a full recording below, or you can click here to book into our next session where we will be joined by Pureprofile (ASX:PPL), PointsBet (ASX: PBH) and Auctus Investments Group (ASX: AVC).

‘The Insider’ is a great way to hear directly from the CEOs of fast growing Australian businesses. You will get valuable insights to their industries and companies future prospects.

 

The Insider: Meet the CEOs – Event Details:

Date: Wednesday, 3rd March
Time: 12pm AEDT
Format: Online, 3 x 15 minute presentations

This is a free event. Click here to book your spot.

 

Sources:

Reach does not assume responsibility for the accuracy or completeness of any information provided, and the views expressed are not reflective of Reach Markets position. Any advice contained within this presentation is general advice and does not consider your personal circumstance, you should consider whether it’s appropriate for you. 

The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.

 


General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.

Weekly Trading Sessions

Covering a market update, picking a direction and trade tips for the week

Leave a comment